Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET
Company Participants
Gayathri Diwakar - Head-Investor Relations
Scott Struthers - Founder and Chief Executive Officer
Marc Wilson - Chief Financial Officer
Dana Pizzuti - Chief Medical and Development Officer
Alan Krasner - Chief Endocrinologist
Conference Call Participants
Cory Jubinville - LifeSci Capital
Jessica Fye - J.P. Morgan
Jeff Hung - Morgan Stanley
Charlie Moore - Baird
Dennis Ding - Jefferies
Joe Schwartz - Leerink Partners
Douglas Tsao - H.C. Wainwright
Leland Gershell - Oppenheimer
Catherine Novack - Jones Trading
Yasmeen Rahimi - Piper Sandler
Operator
Welcome to the Crinetics Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks we will hold a question-and-answer session.
I would now like to turn the call over to Gayathri Diwakar of Crinetics. Please go ahead.
Gayathri Diwakar
Thank you operator. Hello everyone and welcome to Crinetics' earnings call. Joining me today are Dr. Scott Struthers, Founder and Chief Executive Officer; and Marc Wilson, Chief Financial Officer. Also joining us for the Q&A portion of the call are Dr. Dana Pizzuti, Chief Medical and Development Officer; and Dr. Alan Krasner, Chief Endocrinologist. A press release announced in the third quarter 2024 financial results was issued today and is also available on our corporate website.
As a reminder, we'll be making forward-looking statements and I invite you to learn more about the risks and uncertainties associated with these statements as disclosed in our SEC filings. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those stated or implied in such statements due to risks and uncertainties associated with the company's business.
These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's news release, the company's other news releases, and Crinetics SEC filings, including its annual report on Form 10-K and quarterly reports on 10-Q. I would also like to specify that the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, November 12, 2024. Crinetics takes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call.
With that, I'll turn the call over to Scott.
Scott Struthers
Thank you, Gayathri. Good afternoon everyone and thank you for joining us on our third quarter 2024 results call. We've had yet another incredibly productive quarter with advancements up and down the pipeline and we continue to strengthen our financial position. For today's call, I will summarize our recent accomplishments shown on Slide 3, preview some of our upcoming events and then hand the call over to Marc, Marc Wilson for a review of our financials. We'll end, as always, by taking your questions.